Table 1

Patient characteristics and previous treatment

Patients	Presentation*	Previous systemic treatment	Duration of disease (years)	Patient	Presentation*	Previous systemic treatment	Duration of disease (years)
*OA, oral aphthous lesions: 6/6;
V, vasculitis in a skin biopsy: 0/6;
GU, genital ulcerations: 6/6;
C, colitis/gastrointestinal vasculitis: 1/6;
A, arthralgia/arthritis (usually a non-symmetric arthritis): 6/6;
TF, thrombophlebitis: 2/6;
SL, skin lesions: 3/6;
BU, bilateral panuveitis (severe panuveitis): 6/6.
Behçet’s disease: n = 6, mean age: 44, range 32–66
Patient 1, M; 38 years, Behçet’s disease	OA + GU, A, TF, BU	Cyclosporine, colchicine, interferon alfa, prednisone	6	Patient 4, M; 56 years, Behçet’s disease	OA + GU, A, SL, BU	Cyclosporine, colchicine, azathioprine	22
Patient 2, M; 32 years, Behçet’s disease	OA + GU, A, SL; C, BU	Azathioprine, interferon alfa	10	Patient 5, M; 34 years, Behçet’s disease	OA + GU, A BU	Interferon alfa	15
Patient 3, F; 37 years, Behçet’s disease	OA + GU, A, TF, SL, BU	Cyclosporine, colchicine, interferon alfa	6	Patient 6, M; 66 years Behçet’s disease	OA + GU A BU	Cyclosporine Interferon alfa Azathioprine, colchicine, prednisone	7
Patient A, F; 31 years, idiopathic uveitis	Prednisone, MTX		5	Patient E, F; 38 years, idiopathic uveitis	Prednisone, cyclosporine		4
Patient B, M; 29 years, idiopathic uveitis	Cyclosporine, prednisone, interferon alfa		7	Patient F, M; 39 years, sarcoidosis	Prednisone, MTX		5
Patient C, F; 62 years, idiopathic uveitis	Prednisone, cyclosporine		2	Patient G, F; 60 years, birdshot	Cyclosporine, prednisone, MTX		10
Patient D, M; 20 years, idiopathic uveitis	Cyclosporine, Cellcept, Octreotide LAR, prednisone		8